ESC Professional Premium Access

Aortic valve stenosis: computed tomography assessment from diagnosis to prognosis

Event: ESC Congress 2022
Topic: Valvular Heart Disease
Session type: Abstract Sessions
Date: 28 August 2022
Time: 14:00 - 15:00

Congress Session

6 presentations in this session

Novel contrast-computed tomography method based on a Gaussian Mixture Model for assessment of fibrocalcific volume in aortic valve stenosis.

Speaker: Doctor M. Lembo (Naples, IT)

Indexing calcium score of the aortic valve to the annulus area improves the grading of aortic stenosis severity in patients within the grey zone of aortic valve calcification

Speaker: Mr D. Gomes (Lisbon, PT)

Evaluation of non-breath-hold, ultra-fast, low-dose high-pitch (flash) CT scan as a practical alternative to standard spiral scan for pre-TAVI patients: a real-world single-center experience

Speaker: Doctor I. Vitkon Barkay (Beer Yakov, IL)

Cardiac damage staging in patients undergoing TAVR. Incremental value of global longitudinal strain and right ventricular-arterial coupling.

Speaker: Doctor E. Gutierrez Ortiz (Madrid, ES)

CT analysis of left ventricular function predicts short term survival in patients following transcatheter aortic valve implantation: 1-year outcome data

Speaker: Mr M. Ijgua (Erlangen, DE)

CT signs of pulmonary hypertension before TAVI: long-term prognosis in a cohort of 469 patients.

Speaker: Doctor B. Alos (Poitiers, FR)

6 speakers from this session

Doctor Maria Lembo

Federico II University Hospital, Naples (Italy)
4 presentations
1 follower

Mr Daniel Gomes

Hospital Santa Cruz, Lisbon (Portugal)
0 follower

Doctor Itzhak Vitkon Barkay

Yitzhak Shamir Medical Center, Beer Yakov (Israel)
0 follower

Doctor Eva Gutierrez Ortiz

Hospital Clinico San Carlos, Madrid (Spain)
0 follower

Mr Mohamed Cherif Ijgua

Friedrich Alexander University Erlangen Nuernberg, Erlangen (Germany)
0 follower

Doctor Benjamin Alos

University Hospital of Poitiers, Poitiers (France)
0 follower

This platform is supported by

logo Novo Nordisk